Journals / Çocuk Enfeksiyon Dergisi / 2020 / Cilt: 14 - Sayı: 2

Pleural Empyema Due To Streptococcus pneumoniae Serotype 1 in an Immunocompetent Child in the 13-valent Pneumococcal Conjugate Vaccine Era

On Üç Valanlı Pnömokok Aşısı Döneminde İmmünkompetan Bir Çocukta Streptococcus pneumoniae Serotip 1’e Bağlı Plevral Ampiyem

Pages
90–93
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this case, we wanted to emphasize that continued surveillance is necessary to determine and monitor S. pneumoniae serotypes in invasive pneumococcal disease including vaccine serotypes, even in the setting of systemic national vaccination program.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The development of pneumococcal conjugate vaccines for infants have been highly successful in controlling the disease caused by virulent vaccine-specific serotypes.
📊
Key Findings & Data:Here, we reported an immunocompetent, 25-month-old boy who is fully vaccinated with 13 valent pneumococcal conjugate vaccine and diagnosed with left sided pleural empyema due to Streptococcus pneumoniae serotype 1.
💡
Conclusion & Impact:In this case, we wanted to emphasize that continued surveillance is necessary to determine and monitor S. pneumoniae serotypes in invasive pneumococcal disease including vaccine serotypes, even in the setting of systemic national vaccination program.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The development of pneumococcal conjugate vaccines for infants have been highly successful in controlling the disease caused by virulent vaccine-specific serotypes. However, there are a few reports on pneumococcal conjugate vaccine failure. Here, we reported an immunocompetent, 25-month-old boy who is fully vaccinated with 13 valent pneumococcal conjugate vaccine and diagnosed with left sided pleural empyema due to Streptococcus pneumoniae serotype 1. In this case, we wanted to emphasize that continued surveillance is necessary to determine and monitor S. pneumoniae serotypes in invasive pneumococcal disease including vaccine serotypes, even in the setting of systemic national vaccination program.

Özet

Konjuge pnömokok aşılarının geliştirilmesi çocuklarda virülan, aşıya özgül serotiplerin neden olduğu hastalıkların kontrolünde çok başarılı olmuştur. Bununla birlikte pnömokokal konjuge aşıların yetersizliğine ilişkin, az sayıda bildiri mevcuttur. Burada, 13 valanlı konjuge pnömokok aşısı ile tam aşılanmış ve Streptococcus pneumoniae serotip 1’e bağlı sol taraflı plevral ampiyem tanısı alan, 25 aylık, immünkompetan bir erkek çocuk sunulmuştur. Bu olgu ile sistemik ulusal aşılama programlarının varlığına rağmen, invaziv pnömokokal hastalıkta aşı serotipleri dahil, S. pneumoniae serotiplerinin belirlenmesi ve izlenmesi için sürveyansın devamının gerektiği vurgulanmıştır.

🔖

Cite This Article

DURMUŞ, S. Y., TANIR, G., ŞAHİN, N. Ü., TEKE, T. A., KAMAN, A., ÖZ, F. N. (2020). Pleural Empyema Due To Streptococcus pneumoniae Serotype 1 in an Immunocompetent Child in the 13-valent Pneumococcal Conjugate Vaccine Era. Çocuk Enfeksiyon Dergisi, Cilt: 14 - Sayı: 2, 90–93. https://ajindex.com/articles/148771

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Ceyhan M, Ozsurekci Y, Gürler N, Ozkan S, Sensoy G, Belet N, et al. Distribution of Streptococcus pneumoniae serotypes that cause parapneumonic empyema in Turkey. Clin Vaccine Immunol 2013
  2. [CrossRef] 2. Dominguez A, Ciruela P, Hernandez S, Garcia-Garcia JJ, Soldevila N, Izquierdo C, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine inpreventing invasive pneumococcal disease in children aged 7-59 months. A matched case control study. PLoS One 2017
  3. e0183191. [CrossRef] 3. Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010
  4. [CrossRef] 4. https://www.saglik.gov.tr/TR,12280/saglik-istatistikleri-yilligi-2015- -guncellenme-tarihi--14122016-.html (Accessed on June 9, 2018). [CrossRef] 5. Tanır Basaranoglu S, Karadag Oncel E, Aykaç K, Ozsurekci Y, Cengiz AB, Kara A, et al. Invasive pneumococcal disease: from a tertiary care hospital in the post-vaccine era. Hum Vaccin Immunother 2017
  5. [CrossRef] 6. Mani CS. Acute pneumonia and its complications. In: Long SS, Pickering LK, Prober CG (eds). Principles and Practice of Pediatric Infectious Diseases. 5th ed. Philadephia: Elsevier Saunders, 2018:238-49. [CrossRef] 7. Olarte L, Barson WJ, Barson RM, Romero JR, Bradley JS, Tan TQ, et al. Pneumococcal pneumonia requiring hospitalization in US children in the 13-valent pneumococcal conjugate vaccine era. Clin Infect Dis 2017
  6. [CrossRef] 8. Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13- valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015
  7. [CrossRef] 9. Dominguez A, Ciruela P, Hernandez S, Garcia-Garcia JJ, Soldevila N, Izquierdo C, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine inpreventing invasive pneumococcal disease in children aged 7-59 months. A matched case control study. PLoS One 2017
  8. e0183191. [CrossRef] 10. Liese JG, Schoen C, van der Linden M, Lehmann L, Goettler D, Keller S, et al. Changes in the incidence and bacterial aetiology of paediatric parapneumonic pleural effusions/empyema in Germany, 2010-2017: a nationwide surveillance study. Clin Microbiol Infect 2019
  9. [CrossRef] 11. Madhi F, Godot C, Bidet P, Bahuaud M, Epaud R, Cohen R. Serotype 3 pneumococcal